NBC Universal, Inc.
From fighting to get shots to a surplus of appointments, a new trend in the Massachusetts vaccine rollout has some health experts concerned.
At UMass Memorial Health Care s vaccination site on Front Street in Worcester, workers went from administering 600 shots a day last week to struggling to fill 500 appointments this week. Download our mobile app for iOS or Android to get alerts for local breaking news and weather. It s very concerning to all of us. We re not filling like we were just days ago. It s been a dramatic change, Candy Szymanski, the clinical supervisor at the site said.
MedRhythms Launches Clinical Trial of Stroke Asset on Walking Outcomes
MedRhythms, a digital therapeutics company building direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury, announces the launch of a clinical trial that will study MR-010, MedRhythms’ acute stroke asset.
The trial, conducted in partnership with and funded by UMass Memorial Healthcare, will examine the impact of MR-010 on acute stroke walking outcomes.
Led by Dr. Brian Silver, Interim Chair in the UMass Department of Neurology, the trial will assess the feasibility of MR-010 to address walking impairments in those in the acute phase of stroke. It will consist of two phases: the first phase will look at the impact of MR-010 within the acute hospital setting, and the second phase will look at the continued impact of the therapeutic post-discharge, MedRhythms notes in a media release.
MedRhythms Initiates Clinical Trial and Expands Pipeline into Acute Stroke
News provided by
Share this article
Share this article
PORTLAND, Maine, April 28, 2021 /PRNewswire/ MedRhythms, a digital therapeutics company building direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury, today announced the launch of a clinical trial that will study MR-010, MedRhythms acute stroke asset. The trial will be in partnership with UMass Memorial Healthcare and will examine the impact of MR-010 on acute stroke walking outcomes.
Stroke is the world s top cause of long-term disability due to the high prevalence of stroke across the globe as well as its devastating health impacts. Over a third of stroke survivors live in the United States and, according to the CDC, approximately 800,000 people in the US suffer a stroke annually.
MedRhythms, a Portland-based digital health startup that uses sensors, software and music to help restore function lost to neurologic disease or injury, on Wednesday announced the launch of a clinical trial related to acute stroke.
The trial will be in partnership with UMass Memorial Healthcare and will examine the effect of a solution developed by the company on walking by patients with acute stroke.
Wednesday s announcement comes as MedRhythms prepares to launch a trial in collaboration with Boston University related to Parkinson s disease in the next few weeks, and amid an ongoing pivotal trial related to chronic stroke that has been expanded to eight trial sites.